Amphivena Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Amphivena Therapeutics, Inc. Overview

Amphivena Therapeutics, Inc. is a privately held, clinical-stage, oncology company based in South San Francisco, CA with a mission to restore anti-cancer immunity in patients and to take cancer treatment beyond the limits of immunotherapy. The company's proprietary Amphivena ReSTORE platform of bivalent T-cell engagers is designed to selectively relieve immune suppression and drive T-cell activation/polarization in patients.

Strategic Profile

The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy, and in parallel, drives improved T cell effector function. The company is advancing AMV564 through Phase 1 clinical development across multiple solid tumor indications and hematologic malignancies.

Competitive Landscape

Amphivena competes in the immuno-oncology and T-cell engager space against established players developing checkpoint inhibitors and bispecific T-cell engaging antibodies. Direct competitors include Roche/Genentech (BiTE platform), Juno Therapeutics/Bristol Myers Squibb (CAR-T), and emerging bispecific companies like Thirty Thirty Therapeutics and Alnylam. Amphivena's differentiation lies in its MDSC-targeting, bivalent T-cell engager approach combined with subcutaneous dosing, positioning it as an adjunct to rather than replacement for checkpoint inhibitors.

Industry Context

Amphivena Therapeutics, Inc. operates in Oncology Drugs.

Key facts

Founded: 2012 · Headquarters: South San Francisco, US · Employees: 17